MONCYTE Health is proud to announce that Prof. Kausik Ray has joined the company as a Scientific Advisor, further strengthening MONCYTE Health’s scientific leadership in cardiometabolic disease.
Prof. Ray is one of the most pre-eminent preventative cardiologists in the world, with over 200,000 citations for his research and over 500 publications in top-quality peer-reviewed journals. He is the Professor of Public Health, Honorary Consultant Cardiologist, Head of Commercial Trials and Deputy Director of the Imperial Clinical Trials Unit at Imperial College London and Immediate Past President of the European Atherosclerosis Society and has been elected as a Fellow of the Academy of Medical Sciences (FMedSci).
Prof. Ray is internationally recognized for his contributions to cardiovascular prevention, lipidology, and cardiometabolic research. He serves as Professor of Public Health at Imperial College London and has played a leading role in advancing the understanding and management of lipid disorders and cardiovascular risk globally. Through his research, clinical leadership, and involvement in international guidelines and major clinical studies, Prof. Ray has helped shape modern approaches to cardiovascular risk reduction.
At MONCYTE Health, the mission is to advance a precision approach to cardiometabolic disease, focusing on uncovering the biological mechanisms that drive residual cardiovascular risk and inflammation. By providing deeper insight into disease biology at the cellular level, MONCYTE aims to support more precise treatment strategies and improve outcomes for patients with cardiometabolic conditions.
Prof. Ray’s extensive clinical expertise and scientific perspective will play an important role as MONCYTE Health continues to develop its platform and expand collaborations with clinical, Pharma and research partners.
“Cardiometabolic disease remains one of the most significant challenges in global health, and there is a clear need for deeper biological understanding of residual cardiovascular risk to improve prevention,” said Prof. Kausik Ray. “I am excited to support MONCYTE Health as it develops innovative approaches to better understand the mechanisms driving cardiovascular risk and inflammation.”
CSO Simon Pfisterer, MONCYTE Health, welcomed Prof. Ray to the advisory team:
“Prof. Ray is one of the most influential voices in cardiovascular prevention and lipid research globally. His scientific insight and clinical experience will be invaluable as we continue to build MONCYTE Health’s precision approach to cardiometabolic disease and work toward translating deeper biological insight into improved patient care.”
The addition of Prof. Ray further strengthens MONCYTE Health’s growing network of scientific advisors and collaborators dedicated to advancing new approaches in cardiometabolic medicine.
MONCYTE Health looks forward to working closely with Prof. Ray as the company continues to develop technologies aimed at transforming the understanding and treatment of cardiovascular disease.
